Antithrombotic therapy optimizationin a patient with coronary heart diseaseand type 2 diabetes mellitus using the combinationof acetylsalicylic acid and rivaroxaban:a clinical case

Abstract

Summary. Cardiovascular diseases, in particular coronary heart disease (CHD), remain the leading cause of death worldwide, accounting
for about 30% of all deaths. A special risk group is represented by patients with a combination of CHD and type 2 diabetes mellitus (DM‑2),
in whom the incidence of cardiovascular complications is 2–4 times higher than those without DM. This is attributed to complex hemostasis disorders, including both platelet and plasma links of blood coagulation. The article presents a clinical case of a 68‑year-old male
patient with multifocal atherosclerosis, CHD and DM‑2, who retained a high thrombotic risk despite standard therapy with acetylsalicylic
acid (ASA). Adding 2.5 mg rivaroxaban twice daily to 75 mg ASA led to a significant improvement in the condition without increasing
hemorrhagic risk. The Russian drug Cruoxaban (Ozone Healthcare Rus LLC, Russia) increases the availability of therapy, improving treatment adherence.

For citation: Plisyuk A.G., Dolgushin G.O. Antithrombotic therapy optimization in a patient with coronary heart disease and type 2 diabetes mellitus
using the combination of acetylsalicylic acid and rivaroxaban: a clinical case. Tromboz, gemostaz i reologiya. 2025;(3):82–86. (In Russ.).

References:

1. Roth G.A., Mensah G.A., Johnson C.O. et al.; GBD-NHLBI-JACC
Global Burden of Cardiovascular Diseases Writing Group.
Global burden of cardiovascular diseases and risk factors,
1990–2019: Update from the GBD 2019 Study. J Am Coll Cardiol.
2020;76(25):2982–3021. DOI: 10.1016/j.jacc.2020.11.010.

2. Low Wang C.C., Hess C.N., Hiatt W.R., Goldfine A.B. Clinical Update: cardiovascular disease in diabetes mellitus: atherosclerotic cardiovascular disease and heart failure in type 2 diabetes mellitus —
mechanisms, management, and clinical considerations. Circulation 2016;133(24):2459–502. DOI: 10.1161/CIRCULATIONAHA.116.022194I:

3. Ferreiro J.L., Angiolillo D.J. Diabetes and antiplatelet therapy
in acute coronary syndrome. Circulation. 2011;123(7):798–813.
DOI: 10.1161/CIRCULATIONAHA.109.913376.

4. Carr M.E. Diabetes mellitus: a hypercoagulable state. J Diabetes Complications. 2001;15(1):44–54. DOI: 10.1016/s1056‑8727(00)00132‑x.

5. Creager M.A., Lüscher T.F., Cosentino F., Beckman J.A. Diabetes
and vascular disease: pathophysiology, clinical consequences,
and medical therapy: PartI. Circulation. 2003;108(12):1527–32. DOI: 10.1161/01.CIR.0000091257.27563.32.

6. Rollini F., Franchi F., Muñiz-Lozano A., Angiolillo D.J. Platelet function profiles in patients with diabetes mellitus. J Cardiovasc Transl
Res. 2013;6(3):329–45. DOI: 10.1007/s12265‑013‑9449‑0.

7. Eikelboom J.W., Connolly S.J., Bosch J. et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med. 2017;377(14):1319–30. DOI: 10.1056/NEJMoa1709118.

8. Steg P.G., Bhatt D.L., Simon T. et al.; THEMIS Steering Committee.
Ticagrelor in patients with stable coronary disease and diabetes.
N Engl J Med. 2019;381(14):1309–20. DOI: 10.1056/NEJMoa1908077.

9. Capodanno D., Bhatt D.L., Eikelboom J.W. et al. Dual-pathway
inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. Nat Rev Cardiol. 2020;17(4):242–57. DOI: 10.1038/s41569‑019‑0314‑y.

10. Cosentino F., Grant P.J., Aboyans V. et al.; ESC Scientific Document
Group. 2019 ESC Guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD.
Eur HeartJ. 2020;41(2):255–323. DOI: 10.1093/eurheartj/ehz486.

11. Braunwald E.An important step for thrombocardiology. N Engl J
Med. 2017;377(14):1387–8. DOI 10.1056/NEJMe1710241.

12. Krempf M., Parhofer K.G., Steg P.G. et al.; Reach Registry Investigators. Cardiovascular event rates in diabetic and nondiabetic individuals with and without established atherothrombosis (from the
REduction of Atherothrombosis for Continued Health [REACH]
Registry). Am J Cardiol. 2010;105(5):667–71. DOI: 10.1016/j.amjcard.2009.10.048.

13. Steffel J., Eikelboom J.W., Anand S.S. et al. The COMPASS
Trial: net clinical benefit of low-dose rivaroxaban plus aspirin as compared with aspirin in patients with chronic vascular
disease. Circulation. 2020;142(1):40–8. DOI: 10.1161/CIRCULATIONAHA.120.046048. Erratum in: Circulation. 2020;142(1):e23. DOI: 10.1161/CIR.0000000000000880.

14. Jang S.Y., Ju E.Y., Cho S.I. et al. Comparison of cardiovascular
risk factors for peripheral artery disease and coronary artery
disease in the Korean population. Korean Circ J. 2013;43(5):316–
28. DOI:10.4070/kcj.2013.43.5.316.

15. Vanassche T., Verhamme P., Anand S.S. et al. Low-dose rivaroxaban plus aspirin in patients with polypharmacy and multimorbidity: an analysis from the COMPASS trial. Eur Heart J Cardiovasc
Pharmacother. 2022;8(5):462–73. DOI: 10.1093/ehjcvp/pvab050.

16. Anand S.S., Jackie Bosch J., Eikelboom J.W. et al.; COMPASS Investigators. Rivaroxaban with or without aspirin in patients with stable
peripheral or carotid artery disease: an international, randomised,
double-blind, placebo-controlled trial. Lancet. 2018;391(10117):219–29 DOI: 10.1016/S0140‑6736(17)32409‑1.

17. Rhee S.Y., Kim Y.S. Peripheral arterial disease in patients with
type 2 diabetes mellitus. Diabetes Metab J. 2015;39(4):283–90.
DOI: 10.4093/dmj.2015.39.4.283.

18. Guzik T.J., Ramasundarahettige C., Pogosova N. et al. Rivaroxaban plus aspirin in obese and overweight patients with vascular disease in the COMPASS trial. J Am Coll Cardiol. 2021;77(5):511–25.
DOI: 10.1016/j.jacc.2020.11.061.

19. American Diabetes Association Professional Practice Committee. 10. Cardiovascular disease and risk management: standards
of medical care in diabetes‑2022. Diabetes Care. 2022;45(Suppl. 1):
S144–S174. DOI: 10.2337/dc22‑S010.

20. Zhuravleva M.V., Panov A.V., Kuksenok A.R.The impact of combination therapy with rivaroxaban and acetylsalicylic acid in patients
with coronary heart disease on the achievement of the target for
reducing mortality from cardiovascular diseases of the Federal
Project “Fight against cardiovascular diseases”. Racional’naya farmakoterapiya v kardiologii. 2022;18(1):56–66. (In Russ.). DOI: 10.20
996/1819‑6446‑2022‑02‑07.

21. Yavelov I.S.The role of acetylsalicylic acid in the treatment of
diseases caused by atherosclerosis. Aterotromboz. 2023;13(1):23–
34. (In Russ.). DOI: 10.21518/at2023‑003.

22. Gallego-Colon E., Bonaventura A., Vecchié A. et al. Cardiology on
the cutting edge: updates from the European Society of Cardiology (ESC) Congress 2020. BMC Cardiovasc Disord. 2020;20(1):448.
DOI: 10.1186/s12872‑020‑01734‑4.

23. Decree of the Government of the Russian Federation of November 30, 2019 N 1569 “On Amendments to the State Program of the Russian Federation” Healthcare Development. Moscow, 2019. 54 pp. (In Russ.). Available at: https://base.garant.ru/73169732/. [Accessed: 15.05.2025].